Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells: Implications for altered expression of T cell receptor in tumor- associated lymphocytes

Journal of Clinical Investigation

Volumn 101, Issue 11, 1998, Pages 2579-2588

  Rabinowich, Hannah ^a,b   Reichert, Torsten E ^b   Kashii, Yoshiro ^b   Gastman, Brian R ^a   Bell, Maria C ^c   Whiteside, Theresa L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Caspases; CD3 ; Programmed cell death; Protease inhibitors; Signal transduction

Indexed keywords

CD3 ANTIGEN; FAS LIGAND; T LYMPHOCYTE RECEPTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CARCINOMA CELL; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; LYMPHOCYTOTOXICITY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0032102258     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI1518     Document Type: Article

References (34)

1. Miescher, S., T.L. Whiteside, S. Carrel, and V. von Fliedner. 1986. Functional properties of tumor infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J. Immunol. 136:1899-1907.
2. Browning, M.J., and W.F. Bodmer. 1992. MHC antigens and cancer: implications for T-cell surveillance. Curr. Opin. Immunol. 4:613-618.
3. Ochoa, A.C., and D.L. Longo. 1995. Alteration of signal transduction in T cells from cancer patients. In Importance Advances in Oncology. V.T. Devita, S. Hellman, and S.A. Rosenberg, editors. J.B. Lippincott Company, Phildelphia, PA. 43-54.
4. lck in T-cell infiltrating human renal cell carcinoma. Cancer Res. 53:5613-5616.
5. Gunji, Y., S. Hori, T. Aoe, T. Asano, T. Ochiai, K. Isono, and T. Saito. 1994. High frequency of patients with abnormal assembly of T cell receptor-CD3 complex in peripheral blood T lymphocytes. Jpn. J. Cancer Res. 85:1189-1192.
6. Lai, P., H. Rabinowich, P.A. Crowley-Nowick, M.C. Bell, G. Mantovani, and T.L. Whiteside. 1996. Alteration in expression and function of signal transducing proteins in tumor-associated T and NK cells in patients with ovarian carcinoma. Clin. Cancer Res. 2:161-173.
7. Zea, A.H., B.D. Cutri, D.L. Longo, W.G. Alvord, S.L. Strobl, H. Mizoguchi, S.P. Creekmore, J.J. O'Shea, G.C. Powers, W.J. Urba, and A.C. Ochoa. 1995. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res. 1:1327-1335.
8. Matsuda, M., M. Petersson, R. Lenkei, J.-L. Raupin, I. Magnusson, H. Mellstedt, P. Anderson, and R. Kiessling. 1995. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int. J. Cancer. 61:765-772.
9. Rabinowich, H., M. Banks, T. Reichert, T.F. Logan, J.M. Kirkwood, and T.L. Whiteside. 1996. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after IL-2 therapy. Clin. Cancer Res. 2:1263-1274.
10. Reichert, T.E., H. Rabinowich, T.J. Johnson, and T.L. Whiteside. 1998. Human immune cells in the tumor miroenvironment: mechanisms responsible for signaling and functional defects. J. Immunother. In press.
11. Aoe, T., Y. Okamoto, and T. Saito. 1995. Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J. Exp. Med. 181:1881-1886.
12. Kono, K., F. Salazar-Onfray, M. Petersson, J. Hansson, G. Masucci, K. Wasserman, T. Nakazawa, P. Anderson, and R. Kiessling. 1996. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell and natural killer cell-mediated cytotoxicity. Eur. J. Immunol. 26:1308-1313.
13. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R.C. Duke. 1995. A role for CD95 ligand in preventing graft rejection. Nature. 377: 630-632.
14. Griffith, T.S., T. Brunner, S.M. Fletcher, D.R. Green, and T.A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1189-1192.
15. O'Connell, J., G.C. O'Sullivan, J.K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1075-1082.
16. Strand, S., W.J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S.M. Mariani, W. Stremmel, P.H. Krammer, and P.R. Galle. 1997. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat. Med. 2:1361-1366.
17. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L.E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J.C. Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand - implications for tumor immune escape. Science. 274:1363-1366.
18. Niehans, G.A., T. Brunner, S.P. Frizelle, J.C. Liston, C.T. Salerno, D.J. Knapp, D.R. Green, and R.A. Kratzke. 1997. Human lung carcinoma express Fas ligand. Cancer Res. 57:1007-1012.
19. Cascino, I., G. Fiucci, G. Papoff, and G. Ruberti. 1995. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol. 154:2706-2713.
20. Cascino, I., G. Papoff, R. De Maria, R. Testi, and G. Ruberti. 1996. Fas/ Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J. Immunol. 156:13-17.
21. Papoff, G., I. Cascino, A. Eramo, G. Starace, D.H. Lynch, and G. Ruberti. 1996. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J. Immunol. 156:4622-4630.
22. Matzinger, P. 1991. The JAM test: a simple assay for DNA fragmentation and cell death. J. Immunol. Methods. 145:185-192.
23. Darzynkiewicz, Z., G. Juan, X. Li, W. Gorczyca, T. Murakami, and F. Traganos. 1997. Cytometry in cell necrobiology - analysis of apoptosis and accidental cell death (necrosis). Cytometry. 27:1-20.
24. Gavrieli, Y., Y. Sherman, and S.A. Ben-Sasson. 1992. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119:493-501.
25. Enari, M., R.V. Talanian, W.W. Wong, and S. Nagala. 1996. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature. 380:723-726.
26. Rabinowich, H., K. Suminami, T. Reichert, M. Bell, P. Crowley-Novik, R.P. Edwards, and T.L. Whiteside. 1996. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int. J. Cancer. 68:276-284.
27. Reap, E.A., K. Roof, K. Maynor, M. Borrero, J. Booker, and P.L. Cohen. 1997. Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interactions. Proc. Natl. Acad. Sci. USA. 94:5750-5755.
28. Rehemtulla, A., C.A. Hamilton, A.M. Chinnaiyan, and V.M. Dixit. 1997. Ultraviolet radiation-induced apoptosis is mediated by activation of CD95 (Fas/Apo-1). J. Biol. Chem. 272:25783-25786.
29. Fulda, S., H. Sieverts, C. Friesen, I. Herr, and K.M. Debatin. 1997. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 57:3823-3829.
30. Wallach, D., M. Boldin, E. Varfolomeev, R. Beyaert, P. Vandenabeele, and W. Fiers. 1997. Cell death induction by receptors of the TNF family: towards a molecular understanding. FEBS Lett. 410:96-106.
31. Los, M., I. Herr, C. Friesen, S. Fulda, K. Schulzeosthoff, and K.M. Debatin. 1997. Cross-resistance of CD95-and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/CED-3 proteases). Blood. 90: 3118-3129.
32. Nicholson, D.W., and N.A. Thornberry. 1997. Caspases: killer proteases. Trends Biochem. Sci. 22:299-306.
33. Miyawaki, T., T. Uehara, R. Nibu, T. Tsuji, A. Yachie, S. Yonehara, and N. Taniguchi. 1992. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J. Immunol. 149:3753-3758.
34. Suda, T., H. Hashimoto, M. Tanaka, T. Ochi, and S. Nagata. 1997. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 186:2045-2050.